Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the Molecular Imaging Branch (MIB) of the National Cancer Institute (NCI), is seeking to renew a licensing fee for the B-hIL2RA transgenic mouse strain. This presolicitation aims to support critical pre-clinical research on photoimmunotherapy (PIT) for cancer. Responses are due by June 8, 2026.
Scope of Work
The MIB conducts pre-clinical research on photoimmunotherapy (PIT), a targeted treatment using light activation to destroy specific cells. A key focus is IL2RA, a protein on regulatory T cells (Tregs), which can hinder immune responses to cancer. The objective is to selectively eliminate IL2RA-expressing Tregs to enhance anti-cancer immunity.
To facilitate this, the MIB utilizes the B-hIL2RA transgenic mouse strain, which expresses the human form of IL2RA. This model is essential for evaluating treatment materials, such as antibodies, intended for future human application. The renewal of the licensing fee for this specific mouse strain is crucial for the MIB's ongoing research program.
Contract & Timeline
- Opportunity Type: Presolicitation
- Set-Aside: None specified
- Response Due: June 8, 2026, 1:00 PM ET
- Published: May 28, 2026
- Department/Agency: Health And Human Services / National Institutes of Health
- Place of Performance: Maryland, United States
Additional Notes
This opportunity is relevant to entities involved in providing or managing licensing for specialized research animals, particularly those critical for advanced biomedical research. For inquiries, contact John Burton at burtonjo@mail.nih.gov.